Skip to content

The comprehensive clinical effect of tramadol and its comparison between morning and afternoon use

The comprehensive clinical effect of tramadol and its comparison between morning and afternoon use

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044369
Enrollment
Unknown
Registered
2021-03-17
Start date
2021-03-15
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

The morning group:tramadol 1.5mg/kg,iv
The afternoon group:tramadol 1.5mg/kg,iv

Sponsors

Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years old; 2. ASA I-II; 3. Willing to participate and able to understand and sign informed consent; 4. BMI 18.5~28.

Exclusion criteria

Exclusion criteria: 1. Chronic pain, long-term use of analgesics and psychotropic drugs (including opioids, NSAIDs and antidepressants); 2. A history of allergy to opioids; 3. Abnormal surgical anesthesia recovery history; 4. Use sedatives and antidepressants 24 hours before surgery; 5. Patients with a history of epilepsy or a family history of epilepsy that cannot be controlled after treatment; 6. Take monoamine oxidase inhibitors or antidepressants within 15 days; 7. Perform liver surgery; 8. Abnormal liver and kidney function before surgery; 9. Pregnant women and women in childbirth; 10. Patients at high risk of emergency, satiety and reflux aspiration; 11. For any reason, it is not suitable to cooperate with the study or the researcher considers it inappropriate to be included in this study; 12. Patients with a history of severe chronic obstructive pulmonary disease (COPD severity grade III or IV), severe or uncontrolled bronchial asthma, pulmonary infection, or bronchiectasis; 13. Patients with acute coronary syndrome, persistent ventricular tachyarrhythmia, or NYHA grade III or IV severe heart disease; 14. Obese patients; 15. Participated in other drug experiments within three months; 16. Difficult airway.

Design outcomes

Primary

MeasureTime frame
Pressure pain threshold;Invasive arterial blood pressure;

Secondary

MeasureTime frame
Heart rate;SPO2;PaO2;PaCO2;nausea;region of interests ventilation,ROI1,ROI2,ROI3,ROI4;respiratory rate;

Countries

China

Contacts

Public ContactLing Dan

Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University

danling1@sohu.com+86 13983072922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026